Melatonin Ameliorates Busulfan-Induced Spermatogonial Stem Cell Oxidative Apoptosis in Mouse Testes

• Published in: Antioxidants & redox signaling Vol. 28; no. 5; p. 385
• Main Authors: Li, Bo, He, Xin, Zhuang, Mengru, Niu, Bowen, Wu, Chongyang, Mu, Hailong, Tang, Furong, Cui, Yanhua, Liu, Weishuai, Zhao, Baoyu, Peng, Sha, Li, Guangpeng, Hua, Jinlian
• Format: Journal Article
• Language: English
• Published: United States 10.02.2018
• Subjects: busulfan; apoptosis; SSCs (spermatogonial stem cells); melatonin; ROS (reactive oxygen species); p53
• ISSN: 1557-7716
• DOI: 10.1089/ars.2016.6792

Many men endure immunosuppressive or anticancer treatments that contain alkylating agents before the age of sexual maturity, especially the increasing number of preadolescent males who undergo busulfan treatment for myeloablative conditioning before hematopoietic stem cell transplantation. Before sperm production, there are no sperm available for cryopreservation. Thus, it is necessary to identify a solution to ameliorate the busulfan-induced damage of spermatogonial stem cells (SSCs). In this study, we demonstrated that melatonin relieved the previously described SSC loss and apoptosis in mouse testes. Melatonin increased the expression of manganese superoxide dismutase (MnSOD), which regulated the production of busulfan-induced reactive oxygen species (ROS). Moreover, melatonin promoted sirtuin type 1 (SIRT1) expression. SIRT1 participated in the deacetylation of p53, which promotes p53 ubiquitin degradation. Decreased concentrations of deacetylated p53 resulted in spermatogonial cell resistance to apoptosis. Acute T cell leukemia cell assay demonstrated that melatonin does not affect busulfan-induced cancer cell apoptosis and ROS. The current evidence suggests that melatonin may alleviate the side effects of alkylating drugs, such as busulfan. Melatonin promoted MnSOD and SIRT1 expression, which successfully ameliorated busulfan-induced SSC apoptosis caused by high concentrations of ROS and p53. Antioxid. Redox Signal. 28, 385-400.